Content about Actavis

September 13, 2013

Actavis has launched a generic version of an extended-release opioid painkiller, the company said.

PARSIPPANY, N.J. — Actavis has launched a generic version of an extended-release opioid painkiller, the company said.

The drug maker announced the launch of oxymorphone extended-release tablets in the 5-mg, 10-mg, 20-mg, 30-mg and 40-mg strengths. Actavis received approval for the drug in July.

The drug is a generic version of Endo's Opana ER. Endo is currently suing Actavis, alleging that Actavis' generic infringes some of its patents. The drug is used for around-the-clock pain relief.

September 10, 2013

Shareholders of Actavis and Warner Chilcott have approved the merger of the two drug makers, the companies said Tuesday.

PARSIPPANY, N.J. — Shareholders of Actavis and Warner Chilcott have approved the merger of the two drug makers, the companies said Tuesday.

The deal, whereby U.S.-based Actavis will acquire Ireland-based Warner Chilcott, is expected to close later this year.

August 29, 2013

Three independent proxy advisory firms are recommending that Actavis shareholders vote in favor of the company's proposed acquisition of Warner Chilcott.

PARSIPPANY, N.J. — Three independent proxy advisory firms are recommending that Actavis shareholders vote in favor of the company's proposed acquisition of Warner Chilcott.

Actavis said Thursday that Institutional Shareholder Services, Glass Lewis and Egan-Jones had issued the recommendation regarding the $8.5 billion acquisition of Ireland-based Warner Chilcott, announced in May.

August 16, 2013

Actavis today announced that James D'Arecca has joined the company as chief accounting officer. He will be reporting to R. Todd Joyce, chief financial officer — global.

PARSIPPANY, N.J. — Actavis today announced that James D'Arecca has joined the company as chief accounting officer. He will be reporting to R. Todd Joyce, chief financial officer — global.

August 9, 2013

Actavis and Warner Chilcott have received approval from all necessary antitrust clearances for their merger from regulators outside the United States, the companies said.

 PARSIPPANY, N.J. — Actavis and Warner Chilcott have received approval from all necessary antitrust clearances for their merger from regulators outside the United States, the companies said Friday.

The drug makers said that the French Competition Authority had approved U.S.-based Actavis' acquisition of Ireland-based Warner Chilcott. The German Federal Cartel Office had previously approved the deal as well.

August 6, 2013

Actavis has acquired global rights to a drug made by a Spanish company for fungal infections of the vagina, the companies said Tuesday.

PARSIPPANY, N.J. — Actavis has acquired global rights to a drug made by a Spanish company for fungal infections of the vagina, the companies said Tuesday.

Actavis and Palau Pharma announced that Actavis Specialty Brands had acquired right's to albaconazole, an orally administered antifungal for vulvo-vaginal candidiasis, onychomycosis and others. The drug, which Palau discovered, is currently in phase-2 clinical trials, and Actavis foresees a potential U.S. commercial launch of the drug in 2017.

July 29, 2013

Actavis hopes to become the first to market a generic drug for treating chronic pain, the company said.

PARSIPPANY, N.J. — Actavis hopes to become the first to market a generic drug for treating chronic pain, the company said Monday.

Actavis said it had filed with the Food and Drug Administration for approval of tapentadol extended-release tablets in the 50-mg, 100-mg, 150-mg and 200-mg strengths. The drug is a generic version of Johnson & Johnson subsidiary Janssen Pharmaceuticals' Nucynta ER. The drug is used as a continuous, around-the-clock analgesic over a long period of time.

July 29, 2013

Actavis is launching new formulations of a drug used to treat tension headaches, the company said Monday.

PARSIPPANY, N.J. — Actavis is launching new formulations of a drug used to treat tension headaches, the company said Monday.

The drug maker announced new formulations for Fioricet (butalbital; acetaminophen; caffeine) capsules and Fioricet with Codeine that reduce the amount of acetaminophen from 325 mg to 300 mg. Actavis said the formulation would provide a safer treatment option for patients.

July 26, 2013

Anda VP purchasing Marc Falkin wrote in an email to coworkers and friends that he would begin working for Actavis as VP marketing, pricing and contract operations for the Parsippany, N.J.-based drug maker's generics business.

WESTON, Fla. — One of Anda's executives is moving to Actavis after 12 years at Anda.

Anda VP purchasing Marc Falkin has announced that he is leaving the company, and will join Actavis as VP marketing, pricing and contract operations for the Parsippany, N.J.-based drug maker's generics business. Anda executive director of purchasing Anthony Mihelich will assume Falkin's responsibilities in the interim.

 

July 16, 2013

The Food and Drug Administration has approved a generic epilepsy and bipolar disorder drug made by Actavis, the drug maker said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic epilepsy and bipolar disorder drug made by Actavis, the drug maker said.

The generic drug maker announced that it had received FDA approval for lamotrigine orally disintegrating tablets in the 25-mg, 50-mg, 100-mg and 200-mg strengths, a generic version of GlaxoSmithKline's Lamictal ODT.

July 15, 2013

The Food and Drug Administration has approved a generic opioid painkiller made by Actavis, the drug maker said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic opioid painkiller made by Actavis, the drug maker said.

July 12, 2013

Actavis is looking to become the first to market a generic drug for epilepsy, the company said.

PARSIPPANY, N.J. — Actavis is looking to become the first to market a generic drug for epilepsy, the company said Friday.

Actavis announced that it had filed with the Food and Drug Administration for lacosamide tablets in the 50-mg, 100-mg, 150-mg and 200-mg strengths. The drug is a generic version of UBC's Vimpat and is used to treat partial-onset seizures in epilepsy patients aged 17 and older.

July 11, 2013

Actavis and Warner Chilcott announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Warner Chilcott.

PARSIPPANY, N.J. — Actavis and Warner Chilcott on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Warner Chilcott. The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  

June 25, 2013

Canadian regulators have approved a drug for treating a condition that affects up to three-quarters of women and causes excessive bleeding from the uterus.

PARSIPPANY, N.J. — Canadian regulators have approved a drug for treating a condition that affects up to three-quarters of women and causes excessive bleeding from the uterus.

June 17, 2013

Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

NEW YORK — Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

June 13, 2013

Drug maker Actavis is working with nonprofit pharmaceutical company Medicines360 to make low-cost intrauterine devices available to women, the two said.

PARSIPPANY, N.J. — Drug maker Actavis is working with nonprofit pharmaceutical company Medicines360 to make low-cost intrauterine devices available to women, the two said.

June 7, 2013

Actavis is hoping to become the first to market generic versions of a contraceptive and a sedative, the drug maker said.

PARSIPPANY, N.J. — Actavis is hoping to become the first to market generic versions of a contraceptive and a sedative, the drug maker said.

May 31, 2013

India-based Sun Pharmaceutical Industries may buy Sweden-based Meda for $5 billion to $6 billion, according to published reports.

NEW YORK — India-based Sun Pharmaceutical Industries may buy Sweden-based Meda for $5 billion to $6 billion, according to published reports.

Reuters reported that the two companies were in talks for Sun to buy Meda in order to boost its generics business in developed markets.

May 30, 2013

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

May 28, 2013

A federal court has blocked Actavis from distributing its generic version of a drug for treating asthma, the company said.

PARSIPPANY, N.J. — A federal court has blocked Actavis from distributing its generic version of a drug for treating asthma, the company said.

Actavis said the U.S. Court of Appeals for the Federal Circuit had issued an injunction against Actavis' distribution of budesonide inhalation suspension at the request of AstraZeneca, which sells the drug under the trade name Pulmicort Respules.

May 20, 2013

Actavis will acquire Warner Chilcott for $8.5 billion, the drug maker said.

PARSIPPANY, N.J. — Actavis will acquire Warner Chilcott for $8.5 billion, the drug maker said Monday.

May 14, 2013

Actavis is continuing to pursue a plan to buy Irish drug maker Warner Chilcott, as the U.S.-based company announced Tuesday its total number of shares and share-purchase options in order to comply with Ireland's merger-and-acquisition rules.

PARSIPPANY, N.J. — Actavis is continuing to pursue a plan to buy Irish drug maker Warner Chilcott, as the U.S.-based company announced Tuesday its total number of shares and share-purchase options in order to comply with Ireland's merger-and-acquisition rules.

Actavis listed about 133.3 million ordinary shares, 1.5 billion restricted shares and 1.26 options to purchase ordinary shares.

May 14, 2013

The Food and Drug Administration will review an experimental contraceptive patch made by Actavis, the drug maker said Tuesday.

PARSIPPANY, N.J. — The Food and Drug Administration will review an experimental contraceptive patch made by Actavis, the drug maker said Tuesday.

Actavis said the FDA accepted for review its application for norethindrone transdermal delivery system. The patch, which does not yet have a brand name, is designed to provide continuous delivery of norethindrone during a once-weekly, seven-day dosing regimen.

May 10, 2013

Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said.

PARSIPPANY, N.J. — Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said Friday.

Actavis, the world's third-largest generic drug maker, said it had entered into early-stage discussions with Warner Chilcott about a potential combination of the two, but that no agreement had been reached, and that it wouldn't issue further comment about the matter.

May 3, 2013

Actavis' had $1.9 billion in sales in first quarter 2013, the drug maker said.

PARSIPPANY, N.J. — Actavis' had $1.9 billion in sales in first quarter 2013, the drug maker said.

The latest figure represented a 24% increase from first quarter 2012's $1.52 billion. "The new Actavis is off to a strong start in 2013, and as a result, we are increasing our 2013 forecast based on the strong performance and execution against our objectives to date," president and CEO Paul Bisaro said.